Veeva Systems (NYSE:VEEV) Releases Q3 2027 Earnings Guidance

Key Points

• Veeva raised its Q3 FY2027 outlook to EPS of $2.33–$2.34 and revenue of $932–$935 million, above consensus estimates of $2.16 EPS and $917.9 million revenue.
• Analyst sentiment remains broadly positive, with 19 Buy ratings, eight Holds and one Sell; the consensus rating is “Moderate Buy” with a $258.08 price target.
• Veeva shares traded near $244.72, while an insider sold 36,000 shares worth about $9 million under a pre-arranged Rule 10b5-1 plan.

Veeva Systems (NYSE:VEEV - Get Free Report) issued an update on its third quarter 2027 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.330-2.340 for the period, compared to the consensus earnings per share estimate of 2.160. The company issued revenue guidance of $932.0 million-$935.0 million, compared to the consensus revenue estimate of $917.9 million. Veeva Systems also updated its FY 2027 guidance to 9.210-9.210 EPS.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Veeva Systems from $317.00 to $320.00 and gave the stock an "overweight" rating in a report on Thursday, June 4th. The Goldman Sachs Group dropped their target price on Veeva Systems from $190.00 to $165.00 and set a "sell" rating for the company in a research report on Thursday, June 4th. Oppenheimer increased their price objective on Veeva Systems from $225.00 to $300.00 and gave the company an "outperform" rating in a research note on Monday, August 17th. Piper Sandler assumed coverage on shares of Veeva Systems in a research note on Monday. They issued an "overweight" rating and a $295.00 price target for the company. Finally, BNP Paribas Exane reaffirmed an "outperform" rating and set a $285.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Nineteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $258.08.

Veeva Systems Stock Performance

NYSE:VEEV traded down $2.06 during mid-day trading on Wednesday, reaching $244.72. The stock had a trading volume of 1,432,545 shares, compared to its average volume of 2,452,867. Veeva Systems has a twelve month low of $148.05 and a twelve month high of $310.50. The firm has a market capitalization of $39.75 billion, a price-to-earnings ratio of 43.62, a PEG ratio of 1.07 and a beta of 0.92. The business has a 50 day simple moving average of $201.60 and a 200 day simple moving average of $182.61.

Veeva Systems (NYSE:VEEV - Get Free Report) last released its quarterly earnings data on Wednesday, June 3rd. The technology company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. Veeva Systems had a return on equity of 13.72% and a net margin of 28.37%.The firm had revenue of $882.95 million during the quarter, compared to analysts' expectations of $857.73 million. During the same quarter in the prior year, the business posted $1.97 earnings per share. Veeva Systems's revenue was up 16.3% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. As a group, sell-side analysts expect that Veeva Systems will post 6.64 earnings per share for the current year.

Insider Buying and Selling

In other Veeva Systems news, insider Thomas D. Schwenger sold 36,000 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the transaction, the insider directly owned 19,449 shares in the company, valued at approximately $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.60% of the company's stock.

More Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Major customer wins strengthen Vault CRM adoption. Biogen and Regeneron both committed to Veeva Vault CRM globally. The agreements support Veeva’s position in life-sciences commercial software and could contribute to future subscription growth. Veeva Vault CRM Selected by Biogen Veeva Vault CRM Selected by Regeneron
• Positive Sentiment: Truist said the wins reinforce Veeva’s market leadership. The bank characterized Vault CRM as the clear leader in life-sciences CRM ahead of earnings, providing a favorable read-through on competitive positioning and demand. Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings
• Positive Sentiment: Needham reaffirmed its “Buy” rating. The repeated bullish recommendation adds support to the investment case as investors assess Veeva’s growth prospects and valuation. Needham Reaffirms Buy Rating
• Neutral Sentiment: Piper Sandler initiated coverage. New analyst coverage may increase institutional attention, although the article does not specify the firm’s rating or price target. Veeva Coverage Initiated at Piper Sandler
• Neutral Sentiment: Earnings remain the near-term catalyst. Veeva is scheduled to report second-quarter results after the bell. Its previous quarter exceeded consensus estimates, with revenue up 16.3% year over year, so investors will focus on results, subscription growth, and forward guidance. What to Expect From Veeva Systems's Q2 Earnings

Institutional Trading of Veeva Systems

A number of institutional investors have recently bought and sold shares of VEEV. State Street Corp increased its holdings in Veeva Systems by 2.4% during the 4th quarter. State Street Corp now owns 3,589,425 shares of the technology company's stock valued at $801,267,000 after acquiring an additional 85,695 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Veeva Systems by 31.2% in the third quarter. AQR Capital Management LLC now owns 2,412,210 shares of the technology company's stock valued at $706,078,000 after purchasing an additional 574,164 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Veeva Systems by 12.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,728,089 shares of the technology company's stock valued at $385,761,000 after purchasing an additional 189,093 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Veeva Systems by 1.3% in the third quarter. Wellington Management Group LLP now owns 1,466,827 shares of the technology company's stock valued at $436,982,000 after purchasing an additional 18,349 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Veeva Systems by 11.4% during the 3rd quarter. Bank of America Corp DE now owns 1,419,717 shares of the technology company's stock worth $422,948,000 after purchasing an additional 144,982 shares in the last quarter. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Veeva Systems Company Profile

Veeva Systems NYSE: VEEV is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva's product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source